WHAT IS CLAIMED IS:

1. A dosage form of 6-(cyclopropaneamido)-4-((2-methoxy-3-(1-methyl-1H-1,2,4-triazol-3-yl)phenyl)amino)-N-(methyl-d3)pyridazine-3-carboxamide (BMS-986165), the dosage form comprising a dispersion of amorphous BMS-986165 dispersed in a polymer matrix.

2. The dosage form according to claim 1, wherein the polymer matrix comprises hydroxypropyl methylcellulose acetate succinate (HPMCAS).

3. The dosage form according to claim 1, wherein the dispersion of amorphous BMS-986165 dispersed in a polymer matrix is a spray-dried dispersion.

4. The dosage form according to claim 1, further comprising a crystallization inhibitor.

5. The dosage form according to claim 4, wherein the crystallization inhibitor is hydroxypropyl methylcellulose acetate succinate (HPMCAS).

6. The dosage form according to any one of claims 1–5, wherein the dispersion of amorphous BMS-986165 dispersed in a polymer matrix comprises an amount of amorphous BMS-986165 that is at least about 10% w/w of the dispersion.

7. The dosage form according to any one of claims 1–5, wherein the dispersion of amorphous BMS-986165 dispersed in a polymer matrix comprises an amount of amorphous BMS-986165 that is about 15% w/w of the dispersion.

8. The dosage form according to any one of claims 1–5, wherein the dispersion of amorphous BMS-986165 dispersed in a polymer matrix comprises an amount of amorphous BMS-986165 that is no greater than about 25% w/w of the dispersion.

9. The dosage form according to any one of claims 1–5, wherein the proportion of amorphous BMS-986165 to polymer in the dispersion is about 15% w/w amorphous BMS-986165 to about 85% w/w polymer.

10. The dosage form according to any one of claims 1–9, wherein the dosage form is free of crystalline BMS-986165 following storage at 40°C / 75% Relative Humidity for at least three months.

11. The dosage form according to any one of claims 1–9, wherein the dosage form is free of crystalline BMS-986165 following storage at 40°C / 75% Relative Humidity for at least six months.

12. The dosage form according to any one of claims 1–11, wherein the amorphous BMS-986165 in the dosage form exhibits less than 5% degradation when the dosage form is stored at 40 °C / 75% Relative Humidity for at least six months.

13. The dosage form according to any one of claims 1–12, wherein at least about 80% of the amorphous BMS-986165 within the dosage form is released by about 30 minutes after the dosage form is placed in media having a pH from about 1 to about 2.

14. The dosage form according to any one of claims 1–13, wherein at least about 80% of the amorphous BMS-986165 within the dosage form is released by about 30 minutes after the dosage form is placed in media having a pH from about 6 to about 7.

15. The dosage form according to any one of claims 1–14, wherein the dosage form is a tablet containing about 12 mg of amorphous BMS-986165.

16. The dosage form according to claim 15, wherein the tablet has a tablet weight that is no greater than about 400 mg.

17. The dosage form according to any one of claims 15 and 16, wherein the dosage form exhibits improved bioavailability compared to an alternative dosage form comprising

about 12 mg of crystalline 6-(cyclopropaneamido)-4-((2-methoxy-3-(1-methyl-1H-1,2,4-triazol-3-yl)phenyl)amino)-N-(methyl-d3)pyridazine-3-carboxamide.

18. A dosage form comprising amorphous 6-(cyclopropaneamido)-4-((2-methoxy-3-(1-methyl-1H-1,2,4-triazol-3-yl)phenyl)amino)-N-(methyl-d3)pyridazine-3-carboxamide (BMS-986165) dispersed in a polymer matrix, microcrystalline cellulose, lactose, croscarmellose, magnesium stearate, and silicon dioxide.

19. The dosage form according to claim 18, wherein the dosage form comprises: 20% w/w of the amorphous BMS-986165 dispersed in a polymer matrix, wherein said amorphous BMS-986165 dispersed in a polymer matrix is 15% w/w amorphous BMS-986165 : 85% polymer; 51.25% w/w microcrystalline cellulose; 22% w/w lactose anhydrous; 5% w/w croscarmellose sodium; 0.75% magnesium stearate; and 1% w/w silicon dioxide.

20. The dosage form according to claim 19, wherein the dosage form is made by a process comprising granulation, and wherein the 5% w/w croscarmellose sodium is 1:1 intragranular:extragranular, and wherein the 0.75% magnesium stearate is 1:2 intragranular:extragranular.

21. The dosage form according to any one of claims 18–19, wherein the dosage form is made by a process comprising direct compression.

22. The dosage form according to any one of claims 18–21, wherein the dosage form comprises about 1 mg to about 12 mg of amorphous BMS-986165.

23. The dosage form according to any one of claims 18–22, wherein the dosage form is a tablet for oral administration.

24. The dosage form according to any one of claims 18–23, wherein the dosage form exhibits improved bioavailability compared to an alternative dosage form comprising

crystalline BMS-986165, when the dosage form and the alternative dosage form comprise the same amount of BMS-986165.

25. The dosage form according to claim 24, wherein the improved bioavailability is determined by a crossover animal study.

26. The dosage form according to claim 24, wherein the improved bioavailability is determined by comparing the percent dissolved BMS-986165 from the dosage form to the percent dissolved BMS-986165 from the alternative dosage form, in an *in vitro* dissolution test in biorelevant fasted state simulated intestinal fluid (FaSSIF) (pH 6.5) at a temperature of 37 ºC, using paddles and a rotation speed of 75 rpm.

27. An oral dosage form comprising amorphous 6-(cyclopropaneamido)-4-((2-methoxy-3-(1-methyl-1H-1,2,4-triazol-3-yl)phenyl)amino)-N-(methyl-d3)pyridazine-3-carboxamide (BMS-986165) dispersed in a polymer matrix, wherein the bioavailability of BMS-986165 from the oral dosage form when the oral dosage form is to be administered to a subject concurrently with a proton pump inhibitor, differs by no more than 25% from the bioavailability of BMS-986165 from the oral dosage form when the oral dosage form is not to be administered to the subject concurrently with a proton pump inhibitor, wherein the bioavailability of BMS-986165 from the oral dosage form is measured by area under the curve of a plasma-concentration-versus-time curve.

28. Use of the dosage form according to any one of claims 1–26 in the manufacture of a medicament for treating an auto-immune disease or auto-inflammatory disease in a subject.

29. Use of the oral dosage form according to claim 27 in the manufacture of a medicament for treating an auto-immune disease or auto-inflammatory disease in a subject.

30. The use according to claim 28, wherein the subject is a human subject.

31. The use according to claim 29, wherein the subject is a human subject.

32. The oral dosage form according to claim 27, wherein the subject is a human subject.

33. The use according to claim 28, wherein a medicament for an inflammatory bowel disease is prepared.

34. The use according to claim 33, wherein the inflammatory bowel disease is ulcerative colitis.

35. The use according to claim 33, wherein the inflammatory bowel disease is Crohn's disease.